Skip to search formSkip to main contentSkip to account menu

Nuclear matrix protein 22

Known as: NMP22 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Nuclear Proteins
Nuclear matrix protein 22:ACnc:Pt:Urine:QnNuclear matrix protein 22:PrThr:Pt:Urine:Ord

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial
Study Type – Decision analysis (based on alternative scenarios) 
2008
2008
Impact of risk factors on the performance of the nuclear matrix protein 22 point‐of‐care test for bladder cancer detection
To evaluate the impact of different risk factors and symptoms on the performance characteristics of the nuclear matrix protein 22… 
2008
2008
Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
INTRODUCTION The aim of this study was to determine the diagnostic value of urine nuclear matrix protein 22 (NMP22) level in… 
Highly Cited
2007
Highly Cited
2007
Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Highly Cited
2005
Highly Cited
2005
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
PURPOSE We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1… 
2004
2004
How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer.
A handful of cancer biomarkers are currently used routinely for population screening, disease diagnosis, prognosis, monitoring of… 
2000
2000
Comparison of BTA stat and NMP22 Tests in the Detection of Bladder Cancer
Objective: This study aimed to compare the BTA (bladder tumour antigen) stat and urinary nuclear matrix protein (NMP22) test s in… 
Highly Cited
1999
Highly Cited
1999
Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
1999
1999
Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional‐cell carcinoma of the bladder
This study compares urine nuclear matrix protein 22 (NMP22) immunoassay and conventional urine cytologic examination for… 
Highly Cited
1996
Highly Cited
1996
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)